La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Seres Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Seres Therapeutics..

Seres Therapeutics (NASDAQ:MCRB) Azioni, Catena delle Opzioni

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.

News

Price Target

Analyst Ratings

MCRB

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $1.25 price target.

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.25) by 32 percent. This is a 3.13 percent decrease over losses of $(0.32) per share from the same period last year.

Earnings

Seres Therapeutics Q3 2024 GAAP EPS $(0.33) Misses $(0.25) Estimate, Seres Had $66.8M In Cash And Cash Equivalents, That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24.
Seres Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.05 in the last quarter, leading to a 9.07% increase in the share price on the following day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.50</td>
<td>-0.50</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.22</td>
<td>-0.27</td>
<td>-0.32</td>
<td>-0.37</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>37.0%</td>
<td>-5.0%</td>
<td>39.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731430900_0.png" alt="eps graph" />
<h3>Market Performance of Seres Therapeutics's Stock</h3>
Shares of Seres Therapeutics were trading at $0.6917 as of November 11. Over the last 52-week period, shares are down 46.78%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MCRB/earnings">To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Seres Therapeutics's Earnings Preview

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero </a>downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight. Seres Therapeutics shares closed at $0.7570 on Wednesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Overweight to Neutral and lowered the price target from $230 to $210. Avery Dennison shares closed at $207.65 on Wednesday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Neutral and announced a $340 price target. Icon shares closed at $280.76 on Wednesday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Andrew Wittmann downgraded WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Outperform to Neutral and maintained the price target of $42. WillScot shares closed at $37.83 on Wednesday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel downgraded the rating for Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) from Overweight to Sector Weight. Verizon shares closed at $42.86 on Wednesday. <a href="https://www.benzinga.com/quote/VZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png" alt="" class="wp-image-611788" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233.png 1262w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ICLR

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

JP Morgan analyst Tessa Romero downgrades Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight.

Downgrades

JP Morgan Downgrades Seres Therapeutics to Underweight

Rumors

Watching Seres Therapeutics; Traders Circulate M&A Blog Unconfirmed Rumor That Nestle Has Said To Have Made A Bid Between $6.90-$7.20/Share

Members of the Board,
We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Science.
We have read a recent media report from Betaville which states that Nestlé S.A. ("Nestlé") approached Seres in July 2024 with an offer to acquire the entire Company for between $6.00 and $6.50 a share. Furthermore, the article states that Seres' Board rejected the offer and instead pursued the sale of the VOWST assets, which was initially announced in June 2024.
This concerns us because Nestlé's offer would have represented a more than 622% premium to the Company's stock price.1 Additionally, it is well known that Seres has been struggling to fund its operations. Investors do not appear to have strong confidence in the Company's ability to turn itself around in the public market, as evidenced by the negative stock price reaction to the August 6, 2024 announcement of the signing of the VOWST sale agreement.2 Nestlé's reported offer could have resulted in a superior outcome for stockholders than the VOWST sale, giving certainty of value to your investors.
If this media report is accurate, that would mean the Board violated its fiduciary duty to stockholders – specifically, its duty to maximize stockholder value – and could be held legally liable. We acknowledge that this information stems from a singular media report, which is why we are asking the Board to provide stockholders with a factual assessment of the contents of the report so that we may make fully informed decisions regarding our investment in the Company.
If you do not address my concerns in a timely fashion, we plan to consider all legal remedies under U.S. federal securities laws, which may potentially include asking a court to void the votes of the Special Meeting of Stockholders based on misleading and incomplete information given to investors.
Time is of the essence, as Seres intends to close the VOWST sale to Nestlé on September 30, 2024. We look forward to hearing from you soon.
Sincerely,
Lucien Selce
&nbsp;
Antoine Khalife
&nbsp;
&nbsp;
MKT Capital Ltd.

Seres Therapeutics Stockholders Publish Open Letter To Board Urging Clarity On Alleged Rejected Nestlé Takeover Offer Of $6.00-$6.50 Per Share Ahead Of VOWST Sale Closing

WIIM

Seres Therapeutics shares are trading higher after the company announced its stockholders voted to approve the previously announced proposed sale of its VOWST business to Société des Produits Nestlé S.A.

<h3>Gainers</h3>
<ul>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 16.8% to $0.29 during Thursday's after-market session. The company's market cap stands at $6.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 6.69% to $6.16. The market value of their outstanding shares is at $3.1 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 6.01% to $0.88. The company's market cap stands at $134.0 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 5.88% to $1.08. The company's market cap stands at $6.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 5.4% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 5.2% to $0.26. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 27.8% to $0.33 during Thursday's after-market session. The company's market cap stands at $15.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 15.34% to $3.81. The market value of their outstanding shares is at $50.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 7.04% to $3.7. The market value of their outstanding shares is at $6.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 6.17% to $0.21. The company's market cap stands at $13.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 5.38% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares declined by 5.12% to $14.27. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIVI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CHRO

CPHI

LIPO

NVNO

STRM

TBIO

TCBP

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Seres Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.

Seres Therapeutics Stockholders Approve Sale Of VOWST To Nestlé Health Science; Sale Expected To Close on September 30

Watching Seres Therapeutics; Traders Circulate Unconfirmed M&A Blog Comments Suggesting Nestle Has Offered To Acquire The Company For $750M, Or $6-$6.50/Share

Seres Therapeutics Shares Halted To The Upside; Up 20.00%

Seres Therapeutics Q2 2024 GAAP EPS $(0.22) Beats $(0.27) Estimate, $71.2M In Cash And Cash Equivalents That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

Seres Therapeutics shares are trading lower after the company annoucned it signed an agreement with Nestle for the sale of its VOWST business.

In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sales targets.&nbsp;
Seres will support ongoing VOWST availability by providing transition services through the first quarter of 2025 and manufacturing support through the end of 2025 (subject to limited extension rights by Nestlé) and will continue to share 50/50 in the profit and loss of the business through the end of 2025.&nbsp;

Health Care

Contracts

General

Seres Therapeutics Has Signed An Agreement With Société Des Produits Nestlé For The Sale Of Its VOWST Business To Nestlé Health Science. Seres Will Receive Capital Infusions, Including An Upfront Payment, A Prepaid Milestone Payment, And An Equity Investment

Seres Therapeutics Q3 2024 Earnings Preview

Seres Therapeutics GAAP EPS of -$0.33 misses by $0.25

"This quarter has been transformational for Seres, highlighted by our positive SER-155 placebo-controlled clinical results, and the sale of VOWST, ...

Seres Therapeutics reports Q3 EPS 58c, consensus (24c)

As of September 30, 2024, Seres had $66.8 million in cash and cash equivalents. Based on existing cash, projected installment payments to be receiv...

Seres Therapeutics expects cash to fund operations into Q4 of 2025

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Seres Therapeutics (MCRB – Research Report). The company's shares...

Seres Therapeutics (MCRB) Gets a Buy from TD Cowen

15:49 EST Correction: Seres reports Q3 EPS from continuing operations (33c) Published first on TheFly – the ultimate source for real-time, market-m...

Correction: Seres reports Q3 EPS from continuing operations (33c)

As of September 30, Seres Therapeutics (MCRB) had $66.8M in cash and cash equivalents. The company expects to fund operations into Q4 of 2025. It s...

Seres reports Q3 EPS from continuing operations (33c), consensus (24c)

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price target of $10....

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AGEN

AXSM

CYCC

HRTX

RIGL

SNDX

SWTX

XFOR

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

Seres Therapeutics

Seres Therapeutics (MCRB) Opzioni

Seres Therapeutics (NASDAQ:MCRB) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO